mhurhangee/ep-ind-claims huggingface dataset:
A method of drying a material, comprising the steps of: - providing a gaseous atmosphere with superheated steam in a housing, the housing having an inlet duct and outlet duct extending downwards from the housing and communicating with the outside, an inlet port being disposed at a free end of the inlet duct and an outlet port being disposed at a free end of the outlet duct, - transporting a material through the inlet duct into the housing, - drying the material in the gaseous atmosphere, - transporting the dried material through the outlet duct out of the housing, - extracting of gaseous atmosphere from a lower region of the housing, by a fan controlled by a control unit on the basis of temperature and steam content information provided by a temperature sensor and a steam content sensor disposed inside the housing, - condensing the extracted gaseous atmosphere and extracting volatile substances which escape from the material into the gaseous atmosphere from the condensate. - providing a gaseous atmosphere with superheated steam in a housing, the housing having an inlet duct and outlet duct extending downwards from the housing and communicating with the outside, an inlet port being disposed at a free end of the inlet duct and an outlet port being disposed at a free end of the outlet duct, - transporting a material through the inlet duct into the housing, - drying the material in the gaseous atmosphere, - transporting the dried material through the outlet duct out of the housing, - extracting of gaseous atmosphere from a lower region of the housing, by a fan controlled by a control unit on the basis of temperature and steam content information provided by a temperature sensor and a steam content sensor disposed inside the housing, - condensing the extracted gaseous atmosphere and extracting volatile substances which escape from the material into the gaseous atmosphere from the condensate.
A session control method in a Converged Internet Protocol, IP, Messaging, CPM, server for supporting a CPM session between a first client subscribing to a CPM service and a second client not subscribing to the CPM service, the session control method comprising the steps of: after the CPM session is initiated between the first and second clients (110, 111) through the CPM server and an Interworking Function, IWF,, receiving a session modification request message including specific media from the first client; sending the session modification request message including the specific media to the IWF through the initiated CPM session; and receiving a response message from the IWF, the response message including a reason for a rejection of the session modification request message including the specific media; wherein the reason for rejection is an indication that the specific media is unsupported by the IWF. after the CPM session is initiated between the first and second clients (110, 111) through the CPM server and an Interworking Function, IWF,, receiving a session modification request message including specific media from the first client; sending the session modification request message including the specific media to the IWF through the initiated CPM session; and receiving a response message from the IWF, the response message including a reason for a rejection of the session modification request message including the specific media; wherein the reason for rejection is an indication that the specific media is unsupported by the IWF.
A machine-readable medium embodying instructions that may be performed by one or more processors, the instructions comprising: instructions for pumping blood from a patient's blood stream into an access line; instructions for introducing an anticoagulant solution into the pumped blood; instructions for filtering the pumped blood; instructions for delivering the pumped blood from the filtering step to a return line; instructions for returning the blood back to the patient's blood stream; instructions for introducing a calcium solution into the filtered blood traveling through the return line characterized by instructions for introducing a substitution fluid from a supply of substitution fluid into the pumped blood traveling through the access line using a first pump coupled to the access line; instructions for introducing the substitution fluid from the supply of substitution fluid into the filtered blood traveling through the return line using a second pump coupled to the return line. instructions for pumping blood from a patient's blood stream into an access line; instructions for introducing an anticoagulant solution into the pumped blood; instructions for filtering the pumped blood; instructions for delivering the pumped blood from the filtering step to a return line; instructions for returning the blood back to the patient's blood stream; instructions for introducing a calcium solution into the filtered blood traveling through the return line characterized by instructions for introducing a substitution fluid from a supply of substitution fluid into the pumped blood traveling through the access line using a first pump coupled to the access line; instructions for introducing the substitution fluid from the supply of substitution fluid into the filtered blood traveling through the return line using a second pump coupled to the return line.
An identification medium which is observed via a linearly polarizing filter, comprising: a first liquid crystal layer for changing a wavelength of light according to a rotational angle of the linearly polarizing filter, wherein the first liquid crystal layer comprises at least one twisted nematic liquid crystal layer, in which a product by multiplying a birefringent value and a spiral pitch of liquid crystal molecules in the liquid crystal layer is greater than at least 3.5 times the wavelength of light having a wavelength of 400 nm to 800 nm and in which the selective reflection by Bragg diffraction is not caused, and a reflection layer; a cholesteric liquid crystal layer (306a, 306b); and a light absorbing layer provided below the cholesteric liquid crystal layer (306a, 306b); wherein an arrangement pattern of the first liquid crystal layer and an arrangement pattern of the cholesteric liquid crystal layer (306a, 306b) are provided at the same side. a first liquid crystal layer for changing a wavelength of light according to a rotational angle of the linearly polarizing filter, wherein the first liquid crystal layer comprises at least one twisted nematic liquid crystal layer, in which a product by multiplying a birefringent value and a spiral pitch of liquid crystal molecules in the liquid crystal layer is greater than at least 3.5 times the wavelength of light having a wavelength of 400 nm to 800 nm and in which the selective reflection by Bragg diffraction is not caused, and a reflection layer; a cholesteric liquid crystal layer (306a, 306b); and a light absorbing layer provided below the cholesteric liquid crystal layer (306a, 306b); wherein an arrangement pattern of the first liquid crystal layer and an arrangement pattern of the cholesteric liquid crystal layer (306a, 306b) are provided at the same side.
A biometric sensor system for detecting biometric parameters, comprising: an implant including a screw configured to span a fracture, the implant comprising at least two embedded sensors embedded in the implant, wherein at least one sensor of the at least two embedded sensors is operable to detect a plurality of biometric parameters including motion at a fracture site, and at least one of the at least two embedded sensors is operable to detect changes in bone density over time; and at least one additional sensor, wherein the at least one additional sensor is located outside of the implant, and the at least one additional sensor is in communication with at least one of the at least two embedded sensors of the implant to facilitate evaluation of bone density over time. an implant including a screw configured to span a fracture, the implant comprising at least two embedded sensors embedded in the implant, wherein at least one sensor of the at least two embedded sensors is operable to detect a plurality of biometric parameters including motion at a fracture site, and at least one of the at least two embedded sensors is operable to detect changes in bone density over time; and at least one sensor of the at least two embedded sensors is operable to detect a plurality of biometric parameters including motion at a fracture site, and at least one of the at least two embedded sensors is operable to detect changes in bone density over time; and at least one additional sensor, wherein the at least one additional sensor is located outside of the implant, and the at least one additional sensor is in communication with at least one of the at least two embedded sensors of the implant to facilitate evaluation of bone density over time.
A method for preparing acellular cartilage grafts comprising: dicing a cartilage of an animal to produce a plurality of cartilage matrices; treating the cartilage matrices of the step with a sodium hydroxide solution at room temperature for about 3-24 hours; subjecting the sodium hydroxide treated cartilage matrices of the step to a disinfection treatment; and subjecting the disinfected cartilage matrices of the step to a supercritical fluid decellularization treatment to produce the acellular cartilage grafts wherein the SCF treatment is conducted under a pressure of about 15-35 MPa (150-350 bar) at a temperature between 30-50 °C for about 100 mins, wherein the SCF treated cartilage grafts are devoid of any cellular matters, so that acellular cartilage grafts are obtained and no additional enzyme digestion treatment is required. dicing a cartilage of an animal to produce a plurality of cartilage matrices; treating the cartilage matrices of the step with a sodium hydroxide solution at room temperature for about 3-24 hours; subjecting the sodium hydroxide treated cartilage matrices of the step to a disinfection treatment; and subjecting the disinfected cartilage matrices of the step to a supercritical fluid decellularization treatment to produce the acellular cartilage grafts wherein the SCF treatment is conducted under a pressure of about 15-35 MPa (150-350 bar) at a temperature between 30-50 °C for about 100 mins, wherein the SCF treated cartilage grafts are devoid of any cellular matters, so that acellular cartilage grafts are obtained and no additional enzyme digestion treatment is required.
A dosage form, comprising: a drug composition comprising sucrose acetate isobutyrate and a first pharmacologically active agent that is methylphenidate or a pharmaceutically acceptable salt thereof; a barrier layer covering at least a portion of the drug composition; and a drug layer covering at least a portion of the barrier layer, wherein the drug layer comprises a second pharmacologically active agent that is methylphenidate or a pharmaceutically acceptable salt thereof, wherein initial release of the first pharmacologically active agent from the dosage form occurs at a time of 5 minutes to 120 minutes when assayed by USP Apparatus II using 750 mL of 0.1 N HCl dissolution medium, a paddle speed of 50 rpm, and a dissolution medium temperature of 37 °C, and wherein the drug composition is encapsulated in a capsule that comprises an outer surface and an inner surface, and the barrier layer covers at least a portion of the outer surface of the capsule. a drug composition comprising sucrose acetate isobutyrate and a first pharmacologically active agent that is methylphenidate or a pharmaceutically acceptable salt thereof; a barrier layer covering at least a portion of the drug composition; and a drug layer covering at least a portion of the barrier layer, wherein the drug layer comprises a second pharmacologically active agent that is methylphenidate or a pharmaceutically acceptable salt thereof, wherein initial release of the first pharmacologically active agent from the dosage form occurs at a time of 5 minutes to 120 minutes when assayed by USP Apparatus II using 750 mL of 0.1 N HCl dissolution medium, a paddle speed of 50 rpm, and a dissolution medium temperature of 37 °C, and wherein the drug composition is encapsulated in a capsule that comprises an outer surface and an inner surface, and the barrier layer covers at least a portion of the outer surface of the capsule.
Clipped twin-shell sunvisor assembly comprising a first shell and a second shell arranged to be joined together for forming a sunvisor core, wherein said assembly comprises a plurality of clips (3A, 3B, 3C, 3D; 30A', 30A", 30B', 30B", 30C', 30C", 30D', 30D") arranged for interacting with corresponding complementary elements (4A, 4B, 4C, 4D; 40A, 40B, 40C, 40D), each of said clips and each of said complementary elements forming part of one of said shells, characterized in that at least when the shells are joined together, said clips are arranged in groups (3, 30) of clips wherein in each group (3, 30) of clips, the clips are arranged so that each clip is placed at a distance from the other clips that is less than 4 cm, each group comprising at least a first clip (3A; 30A'), a second clip (3B; 30B') and a third clip (3C; 30A"), wherein said first clip (3A; 30A') is arranged for blocking movement of a second complementary element (4B, 40B) interacting with said second clip (3B; 30B') in a first sliding direction when the first shell and the second shell are joined together, wherein said second clip (3B; 30B') is arranged for blocking movement of a first complementary element (4A; 40A) interacting with said first clip in a second sliding direction, when the first shell and the second shell are joined together and wherein said third clip (3C, 30A") is arranged for blocking movement of the complementary elements in a third sliding direction which is an opposite direction to said first sliding direction, when the first shell and the second shell are joined together.
A method of determining a transmission power of a transmitter (101, 201, 301), the method comprising: calculating, by a transmission power determining device, a sum power of the transmitter based on a total transmission power, an efficiency of a power amplifier, a power consumption of a baseband processing unit and a power consumption of a radio frequency front end; calculating, by the transmission power determining device, a channel capacity of the transmitter based on the total transmission power, a number of antennas of the transmitter, an interference, a number of receivers, a noise power and a bandwidth; determining, by the transmission power determining device, a transmission power of the transmitter using a first equation based on the sum power and the channel capacity, wherein the interference in the first equation is calculated as a constant; and determining, by the transmission power determining device, the transmission power of the transmitter using a second equation, different from the first equation, based on the sum power and the channel capacity, wherein the interference in the second equation is calculated as a function of the transmission power. calculating, by a transmission power determining device, a sum power of the transmitter based on a total transmission power, an efficiency of a power amplifier, a power consumption of a baseband processing unit and a power consumption of a radio frequency front end; calculating, by the transmission power determining device, a channel capacity of the transmitter based on the total transmission power, a number of antennas of the transmitter, an interference, a number of receivers, a noise power and a bandwidth; determining, by the transmission power determining device, a transmission power of the transmitter using a first equation based on the sum power and the channel capacity, wherein the interference in the first equation is calculated as a constant; and determining, by the transmission power determining device, the transmission power of the transmitter using a second equation, different from the first equation, based on the sum power and the channel capacity, wherein the interference in the second equation is calculated as a function of the transmission power.
An aluminum alloy heat exchanger that is produced by applying a coating material that is prepared by adding a binder to a mixture of an Si powder and a Zn-containing compound flux powder to a surface of an aluminum alloy refrigerant tube, assembling a bare fin that is formed of an Al-Mn-Zn alloy with the refrigerant tube, and brazing the refrigerant tube and the bare fin by heating in an atmosphere-controlled furnace, the refrigerant tube being an aluminum alloy extruded product that comprises 0.6 to 1.7% (mass%, hereinafter the same) of Mn, less than 0.05% of Cu, and less than 0.10% of Si, and optionally further comprises at least one of 0.30% or less of Ti, 0.10% or less of Sr, and 0.3% or less of Zr, with the balance being Al and unavoidable impurities, the Al-Mn-Zn alloy comprising 0.1 to 1.8% of Mn and 0.8 to 3.0% of Zn, and at least one of 0.1 to 1.2% of Si, 0.01 to 0.8% of Fe, 0.05 to 0.5% of Mg, 0.3% or less of Cu, 0.3% or less of Cr, 0.3% or less of Zr, and 0.3% or less of Ti, and optionally at least one of 0.001 to 0.10% of In and 0.001 to 0.10% of Sn, with the balance being Al and unavoidable impurities; a mixing ratio of the Si powder to the Zn-containing compound flux powder being 10:90 to 40:60, the binder being added in an amount of 5 to 40% based on the total amount of the coating material, the coating material being applied to an outer surface of the refrigerant tube so that the total amount of the Si powder and the Zn-containing compound flux powder is 5 to 30 g/m 2, the surface of the refrigerant tube subjected to brazing having a potential lower than that of an area of the refrigerant tube by 20 to 200 mV, and a potential of the fin being lower than that of the area of the refrigerant tube that is deeper than the diffusion depth of Si and Zn.
A method for operating a mobile communication device (102, 202), the method comprising: displaying on the mobile communication device (102, 202) a graphical user interface (600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400) comprising a message display portion, a message composition portion, and a switch and notification portion; the message display portion displaying at least a portion of a message of a first communication session; and the switch and notification portion displaying a notification (610, 704, 1102) including at least a portion of a message of a second communication session; and in response to a user selecting the notification (610, 704, 1102), displaying in the message display portion at least a portion of the same or another message of the second communication session. displaying on the mobile communication device (102, 202) a graphical user interface (600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400) comprising a message display portion, a message composition portion, and a switch and notification portion; the message display portion displaying at least a portion of a message of a first communication session; and the switch and notification portion displaying a notification (610, 704, 1102) including at least a portion of a message of a second communication session; and in response to a user selecting the notification (610, 704, 1102), displaying in the message display portion at least a portion of the same or another message of the second communication session.
An oral dosage form for use in treating osteoporosis, the oral dosage form comprising a safe and effective amount of a pharmaceutical composition comprising: (a) a bisphosphonate which is selected from the group consisting of risedronate, and salts, esters, hydrates, polymorphs, hemihydrates and solvates thereof; (b) from 25 mg to 500 mg of disodium EDTA; and (c) an enteric coating which provides for release of the bisphosphonate and the EDTA in the lower gastrointestinal tract of a mammal; wherein the molar ratio of the disodium EDTA to the bisphosphonate is at least 2:1; and wherein the oral dosage form is administered weekly and contains from 10 to 50 mg risedronate on a risedronate anhydrous monosodium salt basis. (a) a bisphosphonate which is selected from the group consisting of risedronate, and salts, esters, hydrates, polymorphs, hemihydrates and solvates thereof; (b) from 25 mg to 500 mg of disodium EDTA; and (c) an enteric coating which provides for release of the bisphosphonate and the EDTA in the lower gastrointestinal tract of a mammal; wherein the molar ratio of the disodium EDTA to the bisphosphonate is at least 2:1; and wherein the oral dosage form is administered weekly and contains from 10 to 50 mg risedronate on a risedronate anhydrous monosodium salt basis. wherein the molar ratio of the disodium EDTA to the bisphosphonate is at least 2:1; and wherein the oral dosage form is administered weekly and contains from 10 to 50 mg risedronate on a risedronate anhydrous monosodium salt basis.
A method for preparing the analysis of samples of biological origin, characterized in that the biological sample is held in a buffer system with pH 7-10, subsequently, interfering substances present are precipitated out with soluble salts of trivalent lanthanides, excess soluble salts are precipitated out of trivalent lanthanides and separated as precipitate, and the analysis is conducted with the supernatant.
Device for simultaneously filling at least two foods (8, 9) of different compositions, in a free-flowing and/or highly viscous form, into transparent cups of plastics material or glass, by way of a valve head, which comprises nozzle lines (30, 31) with outlet openings (19, 20) for the foods (8, 9), is supplied by dosing devices (1, 2) and is designed, with a relative movement between the cup and the valve head, to fill the cup from the bottom thereof with a first of the foods (8, 9) as the main component part of the filling and with a second of the foods (8, 9) as the additional component part of the filling distributed in the cup in the form of individual portions, wherein, during the filling operation, a control means carries out a distributing of the different foods (8, 9) in the respective cup according to the height level, radial level and quantity of the same by means of alternately opening and closing the nozzle lines (30, 31), wherein the control means comprises a control disk, which is rotatable about a longitudinal axis in the valve head, with control openings (25a, 25b, 25c) which are distributed about said longitudinal axis along a first control circuit and which, when the control disk is rotated in rotational steps out of a first closed position, prior to achieving a second closed position, are movable one after another in an alternating manner into coincidence with auxiliary nozzle inlet openings (26a, 26b, 26c) in a stationary control face of the valve head which lies underneath in a planar manner, which auxiliary nozzle inlet openings (26a, 26b, 26b) are arranged along a second control circuit which is congruent with the first control circuit in the control surface about the longitudinal axis in such a manner that during the filling operation, in a helically increasing manner, individual portions of the second food which forms the additional component part are positionable on the inside wall of the cup by corresponding auxiliary nozzle outlet openings of the device, wherein the auxiliary nozzle outlet openings are connected to the auxiliary nozzle inlet openings (26a, 26b, 26c) via auxiliary nozzle lines, and wherein a main nozzle, the feeding of which with the first food which forms the main component part can be controlled in a known manner by only one rotary slide in the supply line which comes from the associated dosing device, is provided below the control surface in the valve head inside the second control circuits and the auxiliary nozzle inlet openings (26a, 26b, 26c) distributed along the same along the longitudinal axis, characterized in that the device comprises a control shaft, which is connected in a rigid manner to the control disk and is coaxial with respect to the longitudinal axis, for the rotational stepping of said control disk.